Phrontline Biopharma Advances Dual-Payload HER2 ADC TJ106 Toward 2027 IND Filing

New updates have been reported about Phrontline Biopharma.

Phrontline Biopharma has unveiled preclinical data for TJ106, its next-generation biparatopic HER2-targeting antibody-drug conjugate, showing strong activity in HER2-expressing tumor models, including HER2-low and ADC-resistant disease. The findings, presented at the American Association for Cancer Research 2026 meeting, position TJ106 as a potential option for patients who have progressed on prior HER2-directed therapies, including Trastuzumab deruxtecan.

TJ106 combines a biparatopic HER2 antibody, designed to bind two distinct epitopes and promote receptor clustering, with a dual payload consisting of a topoisomerase I inhibitor and a microtubule inhibitor to sustain cytotoxic activity and address resistance mechanisms. Supported by an optimized linker intended to balance plasma stability and intracellular release, the asset has demonstrated consistent tumor growth inhibition across multiple preclinical models, and Phrontline plans to move into IND-enabling studies with an Investigational New Drug submission targeted for early 2027, followed by a global Phase I trial in HER2-expressing solid tumors under dose-optimization principles aligned with U.S. FDA Project Optimus.